Guangdong Medical University, Zhanjiang, China.
Department of Gastroenterology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
Int J Med Sci. 2020 May 29;17(10):1345-1350. doi: 10.7150/ijms.44338. eCollection 2020.
Patients with Wilson disease (WD) progress to cirrhosis at an early age but have good prognoses. This study aimed to delineate hepatic features in WD patients with or without cirrhosis. Medical data were retrospectively collected from 27 July 2015 to 27 June 2018. WD patients were divided into two groups based on whether or not they progressed to cirrhosis. Liver function, portal hypertension features and hematocytopenia rates were compared between groups. The study enrolled 119 WD patients with cirrhosis and 53 WD patients without cirrhosis. There were no differences between groups for liver enzyme levels or incidence rates of Kayser-Fleischer ring (all > 0.05). Ascites and hepatic encephalopathy were nearly absent in both groups, and almost all patients were Child-Pugh group A. However, WD-associated cirrhotic patients had a higher prothrombin time (beta = 0.908, = 0.004) and international normalized ratio (beta = 0.089, = 0.040), wider portal vein diameter (beta = 1.330, < 0.001), and an increased risk of splenomegaly/splenectomy (odds ratio [OR] = 4.36, 95% confidence interval [CI]: 2.15-8.84, < 0.001). Moreover, WD-associated cirrhotic patients have significantly increased risks of leukopenia (OR = 2.30, 95% CI: 1.00-5.25, = 0.049) and thrombocytopenia (OR = 6.89, 95% CI: 2.01-23.59, = 0.002). Despite presenting good outcomes, mild hepatocyte injury, and good hepatic metabolic function, WD-associated cirrhotic patients show more serious impairment of hepatic synthetic function, wider portal vein diameter, and higher risk of splenomegaly due to portal hypertension.
Wilson 病(WD)患者在年轻时就会发展为肝硬化,但预后良好。本研究旨在描述 WD 患者有无肝硬化的肝脏特征。
回顾性收集 2015 年 7 月 27 日至 2018 年 6 月 27 日的医学数据。根据是否进展为肝硬化,将 WD 患者分为两组。比较两组间肝功能、门静脉高压特征和血细胞减少发生率。
研究纳入 119 例肝硬化 WD 患者和 53 例无肝硬化 WD 患者。两组间肝酶水平或凯氏环(均>0.05)发生率无差异。两组均几乎无腹水和肝性脑病,且几乎所有患者均为 Child-Pugh 分级 A。然而,WD 相关肝硬化患者的凝血酶原时间较长(β=0.908,=0.004),国际标准化比值较高(β=0.089,=0.040),门静脉直径较宽(β=1.330,<0.001),脾肿大/脾切除风险增加(比值比[OR] = 4.36,95%置信区间[CI]:2.15-8.84,<0.001)。此外,WD 相关肝硬化患者白细胞减少(OR=2.30,95%CI:1.00-5.25,=0.049)和血小板减少(OR=6.89,95%CI:2.01-23.59,=0.002)的风险显著增加。
尽管 WD 相关肝硬化患者具有良好的结局、轻度肝细胞损伤和良好的肝脏代谢功能,但肝脏合成功能更严重受损,门静脉直径更宽,门静脉高压导致脾肿大的风险更高。